A 12-WEEK TREATMENT WITH BUDESONIDE ORODISPERSIBLE TABLETS IN THE EOS-1 TRIAL FOR INCOMPLETE RESPONDERS SIGNIFICANTLY IMPROVES BOTH INFLAMMATORY AND FIBROSTENOTIC ENDOSCOPIC FEATURES IN ADULT PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS

Stephan Miehlke  1     Christoph Schlag  2     Ulrike von Arnim  3     Javier Molina-Infante  4     Christoph Schmöcker  5     Albert Jan Bredenoord  6     Constanza Ciriza De Los Ríos  7     Stefan Schubert  8     Ahmed Madisch  9     Jamal Hayat  10     Jan Tack  11     Ralph Mueller  12     Roland Greinwald  12     Alex Straumann  13     Alfredo J. Lucendo  14     Stefan Brueckner  15     Stephen E. Attwood  16     Alain M. Schoepfer  17    
1 Center for Digestive Diseases, Internal Medicine Center Eppendorf, Hamburg, Germany
2 Klinikum rechts der Isar - TU München, München, Germany
3 University Hospital Magdeburg, Madgeburg, Germany
4 Hospital San Pedro de Alcantara, Caceres, Spain
5 Sana Klinikum Lichtenberg, Berlin, Germany
6 Academisch Med. Centrum Amsterdam, Amsterdam, Netherlands
7 Hospital 12 de Octubre, Madrid, Spain
8 Gastroenterologist in Private Practice, Berlin, Germany
9 CRH Clinic Hannover, Hannover, Germany
10 St. George`s University Hospitals NHS Trust, London, United Kingdom
11 University Hospital Leuven, Leuven, Belgium
12 Dr. Falk Pharma GmbH, Freiburg, Germany
13 Swiss EoE Research Network, Olten, Switzerland
14 Hospital General de Tomelloso, Tomelloso, Spain
15 Universitätsklinikum Carl Gustav Carus TU Dresden, Dresden, Germany
16 Durham University, North Tyneside, United Kingdom
17 University Hospital (CHUV), Lausanne, Switzerland

Topic
Immunology, Oesophagus, Paediatrics

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing